Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Thc Potency topic
No spam. Unsubscribe anytime.
Debate over THC potency caps pits patient access against public‑health concerns
Summary
A legislative working group heard competing testimony on whether Utah should cap THC potency for medical cannabis products: public‑health advocates urged limits to protect young people and reduce harms; patient representatives and pharmacists warned caps could drive patients to the illicit market and reduce therapeutic options.
Utah’s medical cannabis working group reopened a contentious question: should the state set limits on THC potency for medical cannabis products? The committee heard sharply divergent views from public‑health advocates, patients, pharmacists and industry representatives.
Senate staff presented a preliminary review of other states’ approaches: Connecticut and Vermont cap flower at 30% THC and concentrates at 60%, Massachusetts caps concentrates at 70%, and Mississippi (medical program only) caps flower at 30% and concentrates at 60%. The chair noted Utah law already limits 28‑day purchase quantities but is silent on potency caps.
Walter Plumb of Drug Safe Utah urged strict limits, citing research he said links high‑THC products to increased risk for addiction, cognitive impairment and psychosis. "High THC is associated with greater risk for addiction, cognitive impairment, dependence," Plumb said, and warned that the program’s monthly purchase limits could enable large quantities to be bought and redistributed.
Patient advocates and industry representatives pushed back. Desiree Hennessy of the Utah Patients Coalition said most program patients treat chronic pain and many rely on higher‑THC products for symptom control; she cited state survey data showing teen cannabis use has not risen since the medical program began and said there was no evidence of diversion from the regulated medical market. "If we drop potency, we're asking patients to use more product to get the desired amount," Hennessy said.
Dr. Misty Smith, College of Pharmacy, emphasized the complexity of potency and effect: potency (THC percentage) is only one factor; product constituents, growing conditions and individual tolerance affect outcomes. She and other medical researchers recommended more evidence before imposing arbitrary caps.
Department of Agriculture and Food director DJ (last name) Forsyth and program director (Dr.) Forsyth (Department of Agriculture and Food) said product quality in the licensed medical program is higher than most black‑market or out‑of‑state products, and cautioned that restrictions in the medical channel may simply push patients to unregulated sources. Industry speakers explained how dosage forms (vapes, edibles, flower) differ: a high percentage does not equate to a single large dose and many users take measured, smaller doses of high‑potency products.
The committee did not adopt potency limits. Members said they would continue to collect research and stakeholder input, including examining interstate product flows, the regulated program’s monitoring data, and the health evidence on adolescent harm.
Ending: The working group requested additional research and data collection and encouraged staff to follow up with the Center for Medical Cannabis Research and other experts; no proposed bill was advanced at the meeting.
